Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Fam-trastuzumab deruxtecan-NXKI: Detailed Review of its Transformative R&D Success
2 November 2023
This article summarized the latest R&D progress of Fam-trastuzumab deruxtecan-NXKI, the mechanism of action for Fam-trastuzumab deruxtecan-NXKI, and the drug target R&D trends for Fam-trastuzumab deruxtecan-NXKI.
Latest Hotspot
3 min read
TransCode Therapeutics unveils extended lifespan in mouse models of Glioblastoma treated by its prime candidate, TTX-MC138
2 November 2023
TransCode Therapeutics, Inc., an RNA oncology specialist, today announced improved survival rates in mouse models with human glioblastoma multiforme tumors after treatment with their leading candidate, TTX-MC138.
Drug Insights
4 min read
Unleashing the Power of Doxycycline Calcium: A Comprehensive Review on R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Doxycycline Calcium, the Mechanism of Action for Doxycycline Calcium, and the drug target R&D trends for Doxycycline Calcium.
Latest Hotspot
3 min read
The U.S. FDA grants Santhera approval for AGAMREE® (vamorolone) as a therapeutic for Duchenne Muscular Dystrophy
2 November 2023
Santhera Pharmaceuticals has confirmed that the FDA has granted approval for AGAMREE® (vamorolone) oral suspension 40 mg/ml.
Drug Insights
4 min read
Ciltacabtagene autoleucel Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Ciltacabtagene autoleucel, the Mechanism of Action for Ciltacabtagene autoleucel, and the drug target R&D trends for Ciltacabtagene autoleucel.
Latest Hotspot
3 min read
The commencement of Phase III SAR-bisPSMA by Clarity and PSI has been initiated
2 November 2023
Clarity Pharmaceuticals,along with PSI CRO AG,have initiated an agreement and begun working on Clarity's Phase III diagnostic trial for SAR-bisPSMA involving prostate cancer applicants.
Drug Insights
3 min read
Unleashing the Power of Clocortolone Pivalate: A Comprehensive Review on R&D Breakthroughs
2 November 2023
This article summarized the latest R&D progress of Clocortolone Pivalate, the Mechanism of Action for Clocortolone Pivalate, and the drug target R&D trends for Clocortolone Pivalate.
Latest Hotspot
3 min read
The FDA gives IND approval for Biosyngen's BST02, the first global TIL treatment for liver cancer
2 November 2023
The US FDA has approved Biosyngen's BST02, a TIL therapy for liver cancer, for clinical trials.
Drug Insights
4 min read
A Comprehensive Review of Clofarabine's R&D Innovations and Drug Target Mechanism
2 November 2023
This article summarized the latest R&D progress of Clofarabine, the Mechanism of Action for Clofarabine, and the drug target R&D trends for Clofarabine.
Latest Hotspot
3 min read
Deciphera announces positive top line results from pivotal Phase 3 trial of vimseltinib in treatment of Tenosynovial Giant Cell Tumors
2 November 2023
Recently, Deciphera Pharmaceutical announced the positive top-line results of its investigational drug vimseltinib in the pivotal Phase 3 MOTION trial for patients with Tenosynovial Giant Cell Tumor (TGCT).
Valuable Targets
7 min read
Analysis on the Clinical Research Progress of ERK Inhibitor
2 November 2023
ERK, also known as Extracellular Signal-Regulated Kinase, is a crucial protein kinase that plays a significant role in various cellular processes within the human body.
Latest Hotspot
3 min read
The new indication for Sugemalimab has been approved in China, making it the world's first treatment for R/R ENKTL
2 November 2023
Recently, Pfizer announced that the third adaptation of the PD-L1 monoclonal antibody Sugemalimab has been conditionally approved by the National Medical Products Administration (NMPA) of China.